# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-123677
Filing Date
2025-05-21
Accepted
2025-05-21 08:42:50
Documents
19
Period of Report
2025-07-03

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | d921291ddef14a.htm iXBRL | DEF 14A | 675511
6 | GRAPHIC | g921291dsp005.jpg | GRAPHIC | 193715
7 | GRAPHIC | g921291dsp006.jpg | GRAPHIC | 130818
| Complete submission text file | 0001193125-25-123677.txt |  | 2171338

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA | tcrt-20241231.xsd | EX-101.SCH | 3478
3 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE | tcrt-20241231_def.xml | EX-101.DEF | 2544
4 | XBRL TAXONOMY EXTENSION LABEL LINKBASE | tcrt-20241231_lab.xml | EX-101.LAB | 2602
5 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | tcrt-20241231_pre.xml | EX-101.PRE | 1645
22 | EXTRACTED XBRL INSTANCE DOCUMENT | d921291ddef14a_htm.xml | XML | 132785

Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33038 | Film No.: 25970987
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)